clinical trial · NCT03194893
A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
Hoffmann-La Roche·phase3·active not recruiting·n = 200
NeoplasmsAlectinibCrizotinib
brief summary
The purpose of this study is to provide continued treatment with alectinib or crizotinib as applicable to participants with ALK- or RET positive cancer who were previously enrolled in any Roche-sponsored alectinib study and who are deriving continued clinical benefit from alectinib or crizotinib in the parent trial at the time of parent trial closure.
started
Jul 5, 2017
primary completion
May 30, 2026
completion
May 30, 2026
last updated
Feb 20, 2026
official title
A Multicenter, International, Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol